Sabirnetug (ACU193) Case Study: A Next-Generation Anti-Aβ Oligomer Antibody Advancing Disease-Modifying Claims with Translational Biomarker Evidence in Alzheimer’s Therapeutics
11:00 am - Wednesday 4th February 2026
- ACU193 selectively targets soluble amyloid-β oligomers (AβOs), sparing monomers and plaques, minimizing the risk of ARIA while preserving synaptic function
- Enhance safety profiles and therapeutic potential for early Alzheimer’s intervention
- Demonstrated CSF biomarker effects in INTERCEPTAD Phase 1 trial (β p tau181, β Aβ42/40 ratio), validating downstream impact on tau pathology and synaptic markers
- Exploring the ongoing ALTITUDE-AD Phase 2 trial with robust biomarker and cognitive endpoints, designed to confirm mechanistic action and clinical efficacy in early AD, and the implications of this for regulatory success and meaningful patient outcomes
